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Abstract
Migraine without aura is the most common form of migraine, characterized by recurrent disabling
headache and associated autonomic symptoms. To identify common genetic variants for this
migraine type, we analyzed genome-wide association data of 2,326 clinic-based German and
Dutch patients and 4,580 population-matched controls. We selected SNPs from 12 loci with two
or more SNPs with P-values < 1 × 10−5 for follow-up in 2,508 patients and 2,652 controls. Two
loci, i.e. 1q22 (MEF2D) and 3p24 (near TGFBR2) replicated convincingly (P = 4.9 × 10−4, P =
1.0 × 10−4, respectively). Meta-analysis of the discovery and replication data yielded two
additional genome-wide significant (P < 5 × 10−8) loci in PHACTR1 and ASTN2. In addition,
SNPs in two previously reported migraine loci in or near TRPM8 and LRP1 significantly
replicated. This study reveals the first susceptibility loci for migraine without aura, thereby
expanding our knowledge of this debilitating neurological disorder.
Main text
Migraine is a disabling episodic neurovascular brain disorder affecting 12% of the general
population1-4. Migraine attacks are typically characterized by severe throbbing unilateral
headache and nausea, vomiting and photo- and phonophobia (migraine without aura; MO).
In up to one third of patients attacks may be associated with neurological aura symptoms
(migraine with aura; MA). Previous genome-wide association studies (GWAS) identified a
migraine susceptibility locus on chromosome 8q22, close to MTDH, in the clinic-based
International Headache Genetics Consortium (IHGC) MA study5 and three other loci in or
near PRDM16, LRP1, and TRPM8 in the population-based migraine Women’s Genome
Health Study (WGHS)6. For TRPM8 there was suggestive association (P < 1 × 10−5) also in
the clinic-based IHGC MA GWAS5. Here we report the first GWAS in MO, the most
common form of migraine. We analyzed two large samples from headache centres in
Germany and the Netherlands including 2,326 MO patients and 4,580 population-matched
controls (Supplementary Note and Supplementary Fig. 1). A quantile-quantile plot of the
joint analysis (Supplementary Fig. 2) and an overall inflation factor (λ1000) of 1.03 were
used as final quality control measures. The discovery dataset identified one genome-wide
significant (P < 5 × 10−8) locus on chromosome 1q22 as well as eleven additional loci
containing multiple SNPs with suggestive association (P < 1 × 10−5) (Supplementary Table
1). Eighteen SNPs from these 12 loci were taken forward to the replication stage in four
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independent clinic-based European MO samples (2,508 cases and 2,652 controls)
(Supplementary Fig. 1 and Supplementary Table 1). Eight SNPs in six loci showed P-values
< 0.05 in the replication study, and five of these SNPs also showed P-values < 5 × 10−8 in
the meta-analysis combining the discovery and replication cohorts (Table 1, Fig. 1 and
Supplementary Fig. 3). Four loci (1q22, 3p24, 6p24, 9q33) replicated, although replication
was less convincing for loci on 6p24 and 9q33 with replication P-values of 0.012 and 0.018,
respectively, although P-values were < 5 × 10−8 in the overall meta-analysis. In addition, we
tested top SNPs of the four previously identified migraine loci (1p36, 2q37, 8q22, 12q13)5,6
in the replication stage (Fig. 2 and Supplementary Table 1), of which 2q37 and 12q13
convincingly replicated. Because migraine is more prevalent in women, we performed a
gender interaction analysis for the reported SNPs (Supplementary Table 2). No significant
interactions were observed and all SNPs had relatively similar odds ratios in both genders.
To further extend our analyses, we searched for expression quantitative trait loci (eQTLs) in
available data sets of tissues and cell lines7,8, but did not observe consistently significant
eQTLs for any of the SNPs of Table 1.
The 1q22 locus contained six SNPs with genome-wide significant association (P < 5 × 10−8)
already in the discovery stage of the analysis and that were all in close LD (r2 > 0.98). SNPs
rs1050316 and rs3790455 were taken forward to the replication stage and successfully
replicated (overall meta-analysis P-values: 3.21 × 10−10 (OR = 1.19) and 7.06 × 10−11 (OR
= 1.20), respectively) (Table 1, Fig. 1 and Supplementary Fig. 3). All associated SNPs are
located within the MEF2D (myocyte enhancer factor 2D) gene (i.e. intronic and 3′-UTR)
that encodes a transcription factor highly expressed in brain. MEF2D regulates neuronal
differentiation by supporting survival of newly formed neurons9. Perhaps even more
relevant to migraine, neuronal activity-dependent activation of MEF2D restricts the number
of excitatory synapses10. As the migraine brain is hyperexcitable11, it is tempting to
speculate that MEF2D dysregulation may affect neuronal excitatory neurotransmission in
MO patients. There is some evidence for increased glutamate (the main brain excitatory
neurotransmitter) levels in migraine patients12,13 and increased glutamatergic
neurotransmission was reported in a transgenic knock-in mouse model with a pathogenic
human hemiplegic migraine gene mutation14. A role for MEF2D dysregulation in migraine
is also plausible given that several MEF2 target genes have been associated with other
neurological disorders, such as epilepsy15-17. Notably, pituitary adenylate cyclase-activating
polypeptide-38 (PACAP-38), which is encoded by one of the activity-regulated MEF2D
target genes and modulates excitatory synaptic transmission, may trigger migraine-like
attacks in patients with MO18. In mice, PACAP-38 is involved in nitroglycerol-induced
trigeminovascular activation19, the presumed origin of the migraine headache20.
The 3p24 locus contained top SNP rs7640543 (initial P = 2.72 × 10−6, OR = 1.20). This
SNP showed strong replication (P = 1.02 × 10−4) and reached genome-wide significance in
the meta-analysis of the discovery and replication samples (P = 1.17 × 10−9, OR = 1.19)
(Table 1, Fig. 1 and Supplementary Fig. 3). Rs7640543 is located ~200 kb upstream of
TGFBR2 (transforming growth factor beta receptor 2), which encodes a serine-threonine
kinase involved in the regulation of cell proliferation and differentiation as well as
extracellular matrix production21. TGFBR2 is an attractive candidate gene for migraine as
the p.Arg460His missense mutation in TGFBR2 not only causes seemingly monogenic,
familial aortic dissection, but also migrainous headaches in 11 of 14 mutation carriers in a
large multigenerational family22. This may fit with the observation that migraineurs seemed
to have a two-fold increased risk for cervical artery dissection23.
For the 6p24 locus, SNP rs9349379 reached genome-wide significance when combining the
data of the discovery and replication samples (P = 3.20 × 10−8, OR = 0.86) (Table 1, Fig. 1
and Supplementary Fig. 3). Five SNPs (P < 10−5) were taken forward to the replication stage
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(see Supplementary Table 1). All five SNPs are located in PHACTR1 (phosphastase and
actin regulator 1), a member of the PHACTR/scapinin family, which controls synaptic
activity and synapse morphology through regulation of protein phosphatase 1 and actin
binding24,25. PHACTR1 has further been implicated in endothelial cell functioning26 and
susceptibility to early-onset myocardial infarction27. Thus, the link between PHACTR1 and
migraine could be neuronal through aberrant synaptic transmission or vascular since
endothelial dysfunction, cardiovascular disease and myocardial infarction all seemed to be
linked with migraine28. Like TGFBR2, PHACTR1 may also be involved in systemic
vascular disease through a TGFβ signalling pathway.
The 9p33 locus with top SNP rs6478241 reached genome-wide significance in the meta-
analysis of the discovery and replication samples, although there is heterogeneity (I2 = 0.57)
in the replication samples (P = 3.86 × 10−8, OR = 1.16) (Table 1, Fig. 1 and Supplementary
Fig. 3). In one of the four replication cohorts the effect direction was opposite to the
discovery sample and the other replication samples. This locus should be considered
tentative and further studies are needed to confirm its relevance to migraine. Rs6478241 is
located in ASTN2, a member of the astrotactin gene family, which plays a role in glial-
guided migration that seems important for development of the laminar architecture of
cortical regions in the brain29. Although structural abnormalities in migraineurs have been
reported in the somatosensory cortex30 and the cerebellum31, they more likely reflect
degenerative processes related to severe migraine attacks than developmental problems.
Therefore, it remains at present unclear how ASTN2 could play a role in migraine
pathophysiology.
In addition, two of the four previously reported migraine loci5,6 showed significant
association in the current clinic-based MO GWAS. Two top SNPs (r2 = 0.52) in the 2q37
migraine locus reached genome-wide significance in the overall MO meta-analysis
(rs10166942, P = 9.83 × 10−13, OR = 0.78; rs17862920, P = 5.97 × 10−9, OR = 0.77) (Table
1, Fig. 2 and Supplementary Fig. 3). SNP rs10166942 is located about 1 kb upstream of the
predicted transcription start of TRPM8 (transient receptor potential melastatin 8), whereas
rs17862920 is located in the first intron of TRPM8. TRPM8 encodes a cold- and menthol-
activated ion channel that is expressed in sensory neurons. The gene was identified as a
migraine susceptibility gene both in the population-based WGHS migraine GWAS6 and the
clinic-based IHGC MA GWAS5. The effect direction of these SNPs is the same in all three
studies, and the effect size estimates are similar (OR = 0.78 in the clinic-based IHGC MA
study for rs17862920 versus 0.77 in the present study, and OR = 0.85 in the population-
based WGHS migraine study for rs10166942 versus 0.78 in the present study). TRPM8
could be involved in cutaneous allodynia32-34, which is defined as pain due to thermal or
mechanical stimuli that normally do not provoke pain that is present in the majority of
migraine patients.
The top SNP rs11172113 of the previously reported6 12q13 migraine locus reached genome-
wide significance in the overall MO meta-analysis (rs11172113, overall P = 2.97 × 10−8, OR
= 0.86) (Table 1, Fig. 2 and Supplementary Fig. 3). SNP rs11172113 is located within the
first intron of LRP1 that codes for the low density lipoprotein receptor-related protein 1
which is expressed in multiple tissues including neurons and the vasculature. LRP1 is a cell
surface receptor that acts as a sensor of the extracellular environment: it is involved in the
proliferation of vascular smooth muscle cells, and modulates synaptic transmission35,36. A
possible role for LRP1 in migraine can be envisaged because of its neuronal and/or vascular
function.
Addressing the question whether MA and MO represent different disease entities37,38, we
tested the top SNPs from the six loci from the current MO study in silico in our previous
Freilinger et al. Page 4













IHGC MA GWAS data set5 (Supplementary Table 3). Except for the 3p24 locus, all loci
showed P-values below 0.05 in the MA data set and ORs going in the same direction in both
studies. The TRPM8 locus showed the most significant P-value (rs1786920: 2.19 × 10−5,
OR = 0.78 and rs10166942: 1.32 × 10−5, OR = 0.82) in the MA data set. Interestingly,
rs10166942 also showed association in the WGHS migraine study (P = 2.30 × 10−7; OR =
0.86 in the initial scan)6. This suggests that TRPM8 may play a role in various forms of
migraine. In contrast, the SNP rs1835740 in the 8q22 locus in the IHGC MA GWAS5
pointing at MTDH as the putative migraine susceptibility gene5, did not show association in
the present GWAS (P = 0.70) nor the population-based WGHS migraine GWAS6 (P = 0.22).
This may suggest that MTDH confers more susceptibility to aura than to headache.
In conclusion, we present the first GWAS in MO, the most common migraine type, and
identified several loci. Two loci (MEF2D and TGFBR2) showed convincing replication
signals, whereas replication for the PHACTR1 and ASTN2 loci was weaker. Future studies
will need to confirm their role as migraine susceptibility loci. In addition, two of the four
previously identified migraine loci (i.e. TRPM8 and LRP1) replicated in this clinic-based
MO study. Functional studies are necessary to dissect the exact underlying molecular
pathways to identify putative treatment targets for this common debilitating brain disorder.
ONLINE METHODS
Overall study design
The discovery stage of the study was based on an analysis of de novo genotyping in two
large MO sample sets from headache clinics in Germany (Munich/Kiel) and the Netherlands
(Leiden) (Supplementary Fig. 1). Population-matched controls were recruited from studies
with existing genotyping data (for details on study cohorts and controls cf. Supplementary
Note). For both sample sets, raw data were imputed to approximately 1.4M SNPs using
HapMap3 release 239 as reference panel. As an initial step, genome-wide logistic regression
analysis was performed independently in both samples, followed by meta-analysis of the
two datasets. Subsequently, the top SNPs of the meta-analysis were tested for replication in
four smaller clinic-based MO samples from Finland (Helsinki), Spain (Barcelona), Norway
(Trondheim) and the Netherlands (Leiden) (Fig. 1 and Supplementary Fig. 1).
Ethical aspects
Written informed consent was obtained from all participants, and the study was approved by
the respective local research ethics committees of the Klinikum Großhadern, Ludwig-
Maximilians-University in Munich (Germany), the University of Leiden Medical Centre
(The Netherlands), the Helsinki University Central Hospital (Finland), the Vall d’Hebron
Research Institute in Barcelona (Spain), and the Regional Committee for Medical and
Health Research Ethics in Trondheim (Norway).
Discovery stage genotyping
Genomic DNA was extracted from peripheral blood samples according to standard
protocols. Genotyping of the German GWAS sample was performed at Genome Analysis
Center, Helmholtz Zentrum München, Germany using the Illumina Human 610-Quad v1 (n
= 838) or Illumina Human 660W-Quad v1 SNP microarrays according to the Infinium II
protocol from the manufacturer (Illumina Inc., San Diego, CA, USA) (n = 391). Genotype
calling was performed using the Illumina Gencall data analyses software. Genotyping of the
complete Dutch GWAS sample was performed at the Wellcome Trust Sanger Institute using
the Illumina 660W technology. Genotype calling was performed using the Illuminus
software.
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For the replication study, all cases and controls were genotyped at the Wellcome Trust
Sanger Institute using matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry (MS), using the Sequenom MassARRAY™ methodology
(Sequenom Inc, San Diego, CA, USA). Amplification reactions and parameters were based
on the manufacturer’s instructions. Each 384-wells plate contained positive (CEPH DNA)
and negative controls, to check for assay performance and contaminations, respectively.
Spectrocaller software supplied by the manufacturer was used to automatically call the
genotypes. Clusters were checked manually and all doubtful calls were evaluated.
In the replication stage, we selected all loci with at least two SNPs with P < 1 × 10−5 for
follow-up in the discovery stage (see Supplementary Table 1). Two SNPs each were
selected from loci deemed to be most convincing (MEF2D, PHACTR1, near TGFBR2,
FHL5), and one SNP each from the remaining loci (see Supplementary Table 1). At the
PHACTR1 locus, as we observed both effect directions for minor alleles in the discovery
stage, we chose three additional SNPs (for a total of five) for follow-up at this locus to
robustly cover possible heterogeneity at this locus. In addition, the top reported SNPs from
the four previously reported migraine loci (see Supplementary Table 1) were included in the
replication stage.
Quality control
To ensure high data quality, the datasets from the primary study were subjected to per-SNP
and per-sample quality control (QC) before and after imputation. In both cases, cut-offs of
1% for minor allele frequency and 1 × 10−6 for HWE were used for cases and controls
independently (as the cases and controls were genotyped independently in both populations),
and the latter again for the combined set of cases and controls. Further, SNPs with call rates
< 97% were excluded. Subjects with a genotyping rate <97% and subjects which were
closely related to each other (π_hat > 0.15) were removed, as were those with cryptic
relatedness and those deemed to be heterozygosity outliers. In addition, population outliers
were excluded using a manual selection from a multidimensional scaling plot of the
genome-wide IBS pair-wise distance matrix in PLINK.
Before imputation, 452,154 SNPs for 3,772 individuals (1,208 cases and 2,564 controls)
were in the German dataset, and 494,760 SNPs for 3,134 individuals (1,118 cases and 2,016
controls) were in the Dutch dataset.
Imputation
Imputation of the German and Dutch discovery samples was performed using IMPUTE 2
(v2.1.0 for the German samples, v2.1.2 for the Dutch samples)40. For the phased haploid
reference panel, we used HapMap3 release 2 data for the 120 unrelated CEU trios41. We
used the recommended parameters for the imputation, with the exception of a different
number of copying states (κ = 60 for Germans, κ = 80 for Dutch) and a larger buffer size for
the Dutch (500 kb instead of 250 kb). After imputation, we used individual call posterior
probability > 0.9 and info measure I(A) > 0.6 as cut-offs to ensure high imputation data
quality. From 1,411,821 SNPs after imputation, 165,433 SNPs were dropped due to QC
reasons.
Statistical analysis
For the GWA data from the two initial study samples, we analyzed the imputed allele
dosage data with the SNPTEST software (version 2.2.0; see Web Resources) to generate
population-specific summary statistics. We used the presence of migraine as a binary
phenotype, and assumed an additive model. Consistent with our previous clinic-based MA
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GWA study5 the association analysis was not corrected for age and gender. The primary
reason for not using age as a covariate was that we lack age information for some of the
control cohorts. However the majority of the individuals in the cohorts were of working age,
similar to our case samples. The missing data score likelihood option was used for handling
missing data. For the replication studies, genotyped markers were analyzed using the same
model as the discovery samples for the population-specific results.
A fixed-effect meta-analysis of the summary statistics was conducted using GWAMA42 (see
Web Resources) first on the two discovery samples for the primary results. In the discovery
sample meta-analysis, only SNPs that were present in both datasets were retained and
filtered for the heterogeneity measure I2 < 0.5. This moderately high threshold for I2 was
chosen to reflect the expectation of some differences in association signals of common
markers due to varying LD structure. After replication, all six study sets (two discovery and
four replication samples) were included in the overall meta-analysis. Reasonable genomic
inflation was observed (λ = 1.095, λ1000 = 1.031). Consistency of allelic effects across
studies was examined utilising the Cochran’s Q43 and I2 metrics44. Between-study (effect)
heterogeneity was indicated by Q-statistic p-values (P ≤ 0.1) and moderate (25-50%) or
larger I2 values45. Meta-analysis of SNPs associated with P ≤ 1 × 10−5 and showing
evidence of effect heterogeneity were also analysed using a random-effects model46.
Manhattan and quantile-quantile plots were generated from the resulting data of 1,246,388
SNPs (Supplementary Fig. 2).
In the gender effects analysis, we analysed the effect of including gender information in the
association analysis for the directly genotyped SNPs at each of the newly identified loci. We
analysed the SNPs in PLINK47 using a logistic regression model assuming additive effects
and covariate adjustment for population identity, and compared the output with results from
a males- and females-only analyses. In addition, we compared the results to those of a
regression analysis where an additional interaction component between gender and genotype
was included in the model.
eQTL analysis
In the expression QTL (eQTL) analysis, we assessed publicly available data from two
published eQTL studies7,8. In these datasets, as described in the original publications,
association between the genotypes of the most interesting SNPs and gene expression were
analysed using Spearman rank correlation for all genes within a 2-Mb window surrounding
the SNP of interest. Significance was assessed by comparing the observed P-value at a 0.001
threshold with the minimum P-values from each of the 10,000 permutations of the
expression values relative to genotypes7,8,48. As an additional approach to eQTL, we
explored the NIH Genotype-Tissue Expression (GTEx) database. The GTEx data did not
provide any association (data not shown).
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Figure 1. Regional and forest plots for the novel migraine loci
Regional association plots (generated using LocusZoom (see Web resources)) are shown for
the four novel migraine loci together with a forest plot for the SNP with highest association
for the respective locus (with the number of cases for each sample indicated) (a-d). Each
regional plot shows the chromosomal position (NCBI build 36) of SNPs in the specific
region against the –log10 P-values. The SNP with the highest association signal in each
locus is represented as a purple diamond; the additional SNPs are color-coded according to
the extent of LD with that SNP. Estimated recombination rates (cM/Mb) from HapMap
CEU release 22 are shown as light blue lines. Forest plots are shown for: rs3790455
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(MEF2D) (a), rs7640543 (TGFBR2) (b), rs9349379 (PHACTR1) (c), and rs6478241
(ASTN2) (d). Black squares represent the odds ratios for the individual cohorts; the
horizontal lines represent the 95% confidence intervals. Numbers in parentheses indicate the
number of cases in each cohort.
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Figure 2. Regional and forest plots for the previously reported migraine loci that replicate in the
current MO study
Regional association plots (generated using LocusZoom (see Web resources)) are shown for
the two previously reported migraine loci6 that significantly replicated in the current study
as well as forest plots for the SNP with highest association in these loci (with the number of
cases for each sample indicated) (a and b).
Each regional plot shows the chromosomal position (NCBI build 36) of SNPs in the specific
region against the –log10 P-values. SNP with the highest association signal in each locus is
represented as a purple diamond; the additional SNPs are color-coded according to the
extent of LD with this SNP. Estimated recombination rates (cM/Mb) from HapMap CEU
release 22 are shown as light blue lines. Forest plots are shown for: rs10166942 (TRPM8)
(a) and rs11127113 (LRP1) (b). Black squares represent the odds ratio for the individual
cohorts; the horizontal lines represent the 95% confidence intervals. Numbers in parentheses
indicate the number of cases in each cohort.
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